Here are 1-3 brief analogies for Tango Therapeutics (TNGX):

• Amgen, but only for cancer drug discovery.

• An early-stage Genentech, focused on new cancer cures.

• TNG908: A synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5, developed for cancers with methylthioadenosine phosphorylase deletions.
• Ubiquitin-specific protease 1 (USP1) inhibitor: An inhibitor designed to treat patients with BRCA1 or BRCA2-mutant cancers.
• Target 3: A therapeutic candidate in development for STK11-mutant cancers.

Tango Therapeutics (TNGX) is a biotechnology company focused on discovering and developing drugs for the treatment of cancer. As a company in the drug discovery and development phase, it does not currently sell finished pharmaceutical products directly to individuals or healthcare providers.

Instead, its major customer is another company, Gilead Sciences, Inc. (GILD), through a strategic collaboration for the discovery, development, and commercialization of therapies for cancer patients. This type of collaboration typically involves upfront payments, milestone payments, and potential royalties to Tango Therapeutics from Gilead Sciences.

Malte Peters, Chief Executive Officer

Malte Peters was appointed President and Chief Executive Officer of Tango Therapeutics in January 2026. He has served on Tango's Board of Directors since 2018. Prior to joining Tango, Dr. Peters was the Chief Research and Development Officer at MorphoSys AG, where he oversaw the global regulatory approval of Monjuvi for diffuse large B-cell lymphoma. His career also includes 12 years at Novartis Oncology, contributing to 28 cancer therapy approvals, and serving as Global Head of Clinical Development at Sandoz Biopharmaceuticals, where he led biosimilar submissions.

Daniella Beckman, Chief Financial Officer

Daniella Beckman serves as the Chief Financial Officer of Tango Therapeutics. In this role, she oversees all aspects of the company's financial operations, including budgeting, forecasting, investor relations, and the implementation of financial policies.

Adam Crystal, President, Research & Development

Adam Crystal is the President of Research & Development at Tango Therapeutics.

Jannik N. Andersen, Chief Scientific Officer

Jannik N. Andersen serves as the Chief Scientific Officer at Tango Therapeutics.

Barbara Weber, Executive Chair of the Board

Dr. Barbara Weber was the founding Chief Executive Officer of Tango Therapeutics from its inception in 2017 until January 2026, when she transitioned to Executive Chair for 2026 and will become non-executive chair in 2027. She joined Third Rock Ventures in 2015 to focus on oncology research and development opportunities, playing a leadership role in the creation and launch of Tango Therapeutics, which originated as a Third Rock Ventures concept. Tango Therapeutics was launched with a $55 million Series A investment from Third Rock Ventures, a venture capital firm. Dr. Weber also served as interim Chief Medical Officer for Neon Therapeutics and was involved in creating Relay Therapeutics. Previously, she held senior leadership positions at Novartis and GlaxoSmithKline, and was a Professor of Medicine and Genetics at the University of Pennsylvania School of Medicine, specializing in breast cancer genetics, including contributions to understanding BRCA1/2 mutations.

1. Drug Development and Regulatory Approval Risk: As a biotechnology company, Tango Therapeutics' success is fundamentally dependent on the successful research, development, and regulatory approval of its drug candidates, including TNG908, USP1 inhibitor, and Target 3. Clinical trials are inherently complex, costly, and have a high rate of failure due to issues such as lack of efficacy, safety concerns, or unforeseen side effects. Even if trials are successful, there is no guarantee that regulatory bodies will grant approval for commercialization.
2. Competition Risk: The oncology therapeutic market is highly competitive and rapidly evolving. Tango Therapeutics faces significant competition from larger pharmaceutical companies and other biotechnology firms that are developing similar or alternative cancer treatments. The company's future success relies on its ability to develop therapies that demonstrate superior efficacy, safety, or other advantageous profiles compared to existing or emerging treatments.
3. Reliance on Strategic Collaboration with Gilead Sciences: Tango Therapeutics has a strategic collaboration with Gilead Sciences, Inc., which is critical for the discovery, development, and commercialization of a pipeline of cancer therapies. While this collaboration provides significant resources and expertise, Tango's ability to advance certain programs and realize their full potential is dependent on the continuation and success of this partnership. Any changes in Gilead's strategic priorities, resource allocation, or the terms of the collaboration could materially impact Tango Therapeutics' business and prospects.

Tango Therapeutics (NASDAQ: TNGX) has several oncology programs, with addressable markets primarily focused on genetically defined cancer patient populations in the U.S. Some of its initial product candidates mentioned in the background have been discontinued and replaced with next-generation therapies.

TNG462 (PRMT5 Inhibitor) and TNG456 (Brain-Penetrant PRMT5 Inhibitor)

Tango Therapeutics' lead programs, TNG462 and TNG456, are next-generation protein arginine methyltransferase 5 (PRMT5) inhibitors developed for cancers with methylthioadenosine phosphorylase (MTAP) deletions. TNG908, initially the lead program, was discontinued in November 2024 due to disappointing clinical data in glioblastoma. TNG462 is being developed for non-central nervous system (CNS) cancers, while TNG456 is a brain-penetrant PRMT5 inhibitor for CNS cancers, including glioblastoma.

The addressable market for MTAP-deleted cancers in the U.S. is estimated to be approximately 60,000 treatable cases annually. This includes around 20,000 cases of pancreatic cancer, 22,000 cases of lung cancer, and another 20,000 cases within a histology-selective cohort. MTAP deletion occurs in 10-15% of all cancers, and specifically in 40% of glioblastoma cases.

Ubiquitin-specific Protease 1 (USP1) Inhibitor

Tango Therapeutics had a program for a Ubiquitin-specific protease 1 (USP1) inhibitor, TNG348, intended to treat patients with BRCA1 or BRCA2-mutant cancers. However, the company terminated the development of TNG348 in May 2024 due to observed Grade III/IV liver function abnormalities in patients during a Phase I/II trial. Therefore, there is currently no addressable market for this product.

TNG260 (CoREST Complex Inhibitor) for STK11-Mutant Cancers

Tango Therapeutics is also developing TNG260, a first-in-class CoREST complex inhibitor for STK11-mutant cancers. This program is specifically targeting STK11-mutant lung cancer, particularly STK11-mut/RAS wild-type lung adenocarcinoma, which represents approximately 10% of lung adenocarcinoma cases. While a precise global or U.S. market size for all STK11-mutant cancers was not available, based on available data, the market for STK11-mut/RAS WT lung cancer is a subset of the broader lung cancer population. Given the lung cancer population within MTAP-deleted cancers is estimated at 22,000 annually in the U.S., the addressable market for TNG260 would be a fraction of the overall lung adenocarcinoma patient population in the U.S..

1. Milestone and Royalty Payments from Gilead Sciences Collaboration: Tango Therapeutics has an ongoing strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of cancer therapies. While the research activities under the collaboration concluded in 2025, agreements for future milestones and royalties remain in effect. Gilead has the right to option up to 15 programs, with potential opt-in, extension, and milestone payments of up to $410 million per program, in addition to low double-digit tiered royalties on net sales if products are commercialized.
2. Advancement of Vopimetostat (TNG462) in Clinical Trials: The company's lead program, vopimetostat (formerly TNG908), a synthetic lethal small molecule inhibitor of PRMT5, is a significant future revenue driver. Tango Therapeutics plans to initiate a pivotal study for vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer in 2026. Successful progression of this program through clinical development can unlock substantial milestone payments from existing or new partnerships, paving the way for eventual commercialization.
3. Successful Development of Vopimetostat Combination Therapies: Tango is actively evaluating vopimetostat in combination with RAS-targeted therapies, including collaborations with Revolution Medicines and a new clinical supply agreement with Erasca. Initial Phase 1/2 safety and efficacy data from these combination trials are anticipated in 2026. Positive results could inform an accelerated development path for treating cancers like first-line pancreatic cancer, potentially leading to new partnership agreements or expanded terms, and associated revenue.
4. Progression of Other Pipeline Assets, Notably TNG456: The advancement of other key pipeline candidates, such as TNG456, a next-generation brain-penetrant PRMT5 inhibitor for CNS cancers, represents another potential revenue growth driver. Initial Phase 1/2 safety and efficacy data for TNG456 monotherapy are expected in 2026. Positive data from this and other preclinical or early-stage programs could attract additional collaboration opportunities and associated upfront and milestone payments.

Share Issuance

• In October 2025, Tango Therapeutics announced an underwritten offering of common stock and pre-funded warrants, anticipated to generate approximately $210 million in gross proceeds (around $197 million net proceeds). This offering involved the sale of 21,023,337 shares of common stock at $8.66 per share and pre-funded warrants for up to 3,226,458 shares at $8.659 each.
• The company established a new at-the-market (ATM) offering program in November 2025 with Leerink Partners LLC, allowing for the sale of up to $100 million of its common stock. This new agreement replaced a previous $100 million ATM program with Jefferies LLC that was entered into in September 2022.
• In August 2023, Tango Therapeutics conducted a private investment in public equity (PIPE) financing, agreeing to sell approximately 15.5 million shares of its common stock (or pre-funded warrants) at a price of $5.15 per share, which was expected to yield approximately $80 million in gross proceeds.

Inbound Investments

• A private investment in public equity (PIPE) agreement in October 2025, concurrent with the underwritten offering, involved the sale of 1,732,101 shares at $8.66 per share, expected to generate an additional $15 million in gross proceeds. This PIPE was led by Nextech.
• An $80 million PIPE financing closed in August 2023, led by Nextech and including participation from institutional investors such as Boxer Capital, Bain Capital Life Sciences, Casdin Capital, EcoR1 Capital, Southpoint Capital, Third Rock Ventures, and a large institutional investor.
• In April 2021, Tango Therapeutics became a publicly listed company through a merger with BCTG Acquisition Corp., resulting in gross proceeds of approximately $342 million and a total cash position of about $515 million. This included a common stock PIPE of approximately $186 million at $10.00 per share, led by Boxer Capital, with participation from various institutional investors, including Gilead Sciences.
• An expanded strategic collaboration with Gilead Sciences in August 2020 included a $125 million upfront payment and a $20 million equity investment from Gilead. This expanded collaboration increased the number of targets covered from five to 15, with potential payments of up to $410 million per program in opt-in, extension, and milestone payments.

Capital Expenditures

• In the most recent fiscal year, Tango Therapeutics reported capital expenditures of $1.0 million, which contributed to a negative free cash flow of -$139.9 million as of March 8, 2026.
• Capital expenditures for the most recent quarter (Q4 2025) were -$0.15 million USD.
• Free cash flow of -$146.76 million provided weak coverage of capital expenditures amounting to $950,000, indicating a need for additional external financing to support growth initiatives.